NeoGenomics Inc. Common Stock vs Schwab US Dividend Equity ETF — how do they compare? NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.17B), while Schwab US Dividend Equity ETF trades at $33.95 (market cap $111.61B). The key difference: Schwab US Dividend Equity ETF is far larger — about 51.4× NeoGenomics Inc. Common Stock's market cap, and Schwab US Dividend Equity ETF is more actively traded (25,598,052 versus 1,615,943). Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and Schwab US Dividend Equity ETF for 64 Days on average.
| NEO | SCHD | |
|---|---|---|
Market Cap | $2.17B | $111.61B |
Volume | 1,615,943 | 25,598,052 |
Sector | Health | Broad Market / Factor |
52-Week High | $19.91 | $35.21 |
52-Week Low | $7.19 | $26.44 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $2.47B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SCHD trades at $33.37, up 0.33% with a bullish technical signal from moving averages. Recent news highlights SCHD outperforming the S&P 500 in 2026 and growing its dividend. The ETF's defensive dividend strategy faces scrutiny after missing gains from stocks like Broadcom due to its selection rules.
The outlook remains positive for income investors seeking quality dividend growth with lower risk through diversification. Key risks include interest rate sensitivity and the opportunity cost of excluded high-growth stocks. Current technical strength supports near-term stability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →